8.40↑-0.05 (-0.59%)
12:00 AM,29th Sep 20238.39↑-0.06 (-0.71%)
12:00 AM,29th Sep 2023BSE : 524470
NSE : SYNCOMF
Sector : Health care
ISIN Code : INE312C01025
Last Updated: Sep 29 2023 | 12:00 AM IST
Market Cap (₹ Cr) | 789 |
Turnover (₹ Cr) | 0.09 |
Volume (Shares) | 1089763 |
Face Value | 1 |
52-WK High | 11.60 |
52-WK High Date | 26 Dec 2022 |
52-WK Low | 4.60 |
52-WK Low Date | 29 Mar 2023 |
All Time High | 11.60 |
All Time High Date | 26 Dec 2022 |
All Time Low | 4.60 |
All Time Low Date | 29 Mar 2023 |
Incorporated as a private limited company in 1988 Syncom Formulations (India) was converted into a public limited company in Jun.'92. The company set up a manufacturing facility at Palghar Thane to produce pharmaceutical formulations. Commercial production commenced in Apr.'89. Promoters are Kedarmal Bankda Vijay Kumar Bankda and Ajay Kumar Bankda.In addition to pharmaceutical formulations in the form of tablets capsules liquids and dry powders the company also manufactures injectibles and ear/eye drops on a loan licence basis.In 1994 the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur Madhya Pradesh. The project which was financed through a public issue made in Jan.'94 was completed in 1995.During the year 1997-98 the Company has further diversified into Ethical Operations by introducing the range of prescription formulations.During the year 1998-99 there has been huge expansion of installed capacity and production base. Further the company plans introduction of products in the generic OTC and Ethical Divisions. The export earnings have also registered a growth of more than 100%.During the year 1999-2000 the company and its associates have received export orders worth Rs.700.00 lacs against advance payment and hence better turnover is expected during the year. The company presently exports goods to Guine Ghana Kenya Tanzania Nigeria in Africa Azberjan Nepal and Srilanka in Asia. The company has been approved as a supplier to Central ESI Hospitals and registration of defence services is in its final stages as a result of which will generate substantial sales volume. Keeping in view the shifting consumer preferenes for the use of herbal products the company is aggressively manufacturing and marketing its herbal products like Edicare Attom Megacaps Ecziguard and Yas antacid salt.
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 789 |
EPS - TTM (₹) [S] | 0.22 |
P/E Ratio (X) [S] | 3.09 |
Face Value (₹) | 1 |
Latest Dividend (%) | 3.00 |
Latest Dividend Date | 09 Sep 2022 |
Dividend Yield (%) | - |
Book Value Share (₹) [S] | 2.72 |
P/B Ratio (₹) [S] | 3.09 |
[*C] Consolidated [*S] Standalone |
Scheme Name ↑↓ | Amount Invested ( ₹ Cr ) ↑↓ | No Of Shares ↑↓ | Net Asset (%) ↑↓ |
---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF | 0.00 | 4696 | 0.05 |
Date↑↓ | Broker↑↓ | Action↑↓ | Prices(Rs)↑↓ | Report |
---|---|---|---|---|
Data Not Found |
Today's Low/High | 8.35 8.55 |
Week Low/High | 8.35 9.00 |
Month Low/High | 8.00 9.00 |
Year Low/High | 4.60 12.00 |
All time Low/High | 0.14 12.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | -2.67% | -2.33% | -0.27 | -0.18% |
1 Month | -3.34% | -2.89% | 1.16 | 1.53% |
3 Month | 10.24% | 10.53% | 2.99 | 3.51% |
6 Month | 68.34% | 68.00% | 14.26 | 15.85% |
1 Year | 4.48% | % | 16.70 | 16.77% |
3 Year | 402.99% | % | 73.35 | 74.99% |
Date | Client Name | Exchange | Transaction | Quantity | Price |
---|---|---|---|---|---|
12-01-2022 | ALPHA LEON ENTERPRISES LLP | BSE | BUY | 5931966 | 16.31 |
12-01-2022 | ALPHA LEON ENTERPRISES LLP | BSE | SELL | 6100673 | 17.46 |
04-01-2022 | PRITESH PRAVIN VORA | BSE | SELL | 4213970 | 14.46 |
04-01-2022 | PRITESH PRAVIN VORA | BSE | BUY | 4213970 | 13.48 |
12-10-2021 | TOPGAIN FINANCE PRIVATE LIMITED | BSE | BUY | 4601127 | 12.89 |
12-10-2021 | TOPGAIN FINANCE PRIVATE LIMITED | BSE | SELL | 6281740 | 13.05 |
21-06-2021 | ALPHA LEON ENTERPRISES LLP | BSE | SELL | 6113474 | 8.75 |
21-06-2021 | ALPHA LEON ENTERPRISES LLP | BSE | BUY | 6957164 | 8.44 |
01-06-2021 | TOPGAIN FINANCE PRIVATE LIMITED | BSE | BUY | 7125519 | 7.84 |
01-06-2021 | TOPGAIN FINANCE PRIVATE LIMITED | BSE | SELL | 7768509 | 7.87 |
Load More |
Name | Price(In Rs) | Chg(%) | Mkt Cap(Rs Cr) | Sales(Rs Cr) | Profit(Rs Cr) | EPS(Rs) | P/E(x) |
---|
Category | Share(%) |
---|---|
Promoter | 50.57 |
Financial Institutions Banks | 0.00 |
Foreign Institutional Investors | 0.00 |
Insurance Companies | 0.00 |
Mutual Funds Uti | 0.00 |
Other Institutional Investors | 0.00 |
Indian Public | 45.00 |
Others Non Institutional Investors | 4.43 |
Custodians | 0.00 |
Announcement Date | Purpose | From | To | Remarks |
---|---|---|---|---|
Data Not Found |
Search for Price History
Date | Open | High | Low | Close | Shares | Trades |
---|---|---|---|---|---|---|
Data Not Found |
Load more
Chairman & Wholetime Director : Kedarmal Bankda
Managing Director : Vijay Shankarlal Bankda
Independent Director : Vinod Kumar Kabra
Independent Director : Krishna Das Neema
Independent Director : Praveen Jindal
Whole-time Director : Rinki Bankda
Addtnl Independent Director : Ruchi Jindal
Company Sec. & Compli. Officer : Vaishali Agrawal
Registered Office: 7 Niraj Indl Estate Andheri(E), Off Mahakali Caves Rd,Mumbai,Maharashtra-400093 Ph: 91-22-30887744